Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifampin (unii: vjt6j7r4tr) (rifampin - unii:vjt6j7r4tr), isoniazid (unii: v83o1voz8l) (isoniazid - unii:v83o1voz8l), pyrazinamide (unii: 2kni5n06ti) (pyrazinamide - unii:2kni5n06ti) - rifampin 120 mg - rifater is indicated in the initial phase of the short-course treatment of pulmonary tuberculosis. during this phase, which should last 2 months, rifater should be administered on a daily, continuous basis (see dosage and administration). following the initial phase and treatment with rifater, treatment should be continued with rifampin and isoniazid (e.g., rifamate) for at least 4 months. treatment should be continued for a longer period of time if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is hiv positive. in the treatment of tuberculosis, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. bacteriologic smears or cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to r

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - pyrazinamide; rifampicin; isoniazid - oral tablet - 300mg ; 120mg ; 50mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - pyrazinamide; rifampicin; isoniazid - oral tablet - 300mg ; 120mg ; 50mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - pyrazinamide; rifampicin; isoniazid - oral tablet - 300mg ; 120mg ; 50mg

Īrija - angļu - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - isoniazid; pyrazinamide; rifampicin - tablet - 50 /300 /120 milligram(s) - combinations of drugs for treatment of tuberculosis; rifampicin, pyrazinamide and isoniazid

Kanāda - angļu - Health Canada

sanofi-aventis canada inc - rifampin; isoniazid; pyrazinamide - tablet - 120mg; 50mg; 300mg - rifampin 120mg; isoniazid 50mg; pyrazinamide 300mg - antituberculosis agents

Īrija - angļu - HPRA (Health Products Regulatory Authority)

marion merrell limited - isoniazid pyrazinamide rifampicin - tablets

Indija - angļu - Central Drugs Standard Control Organization

sanofi aventis - rifampicin,pyrazinamide,isoniazid - tab - 120,250,80;mg - 10

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - isoniazid 50mg; pyrazinamide 300mg; rifampicin 120mg - tablet - active: isoniazid 50mg pyrazinamide 300mg rifampicin 120mg excipient: acacia aluminium hydroxide gel dried calcium stearate carmellose sodium colloidal silicon dioxide iron oxide red kaolin light magnesium oxide povidone purified talc sodium laurilsulfate sucrose titanium dioxide